The big news: Medical devices company Supira announced $120 million in an oversubscribed Series E funding round, led by new investors Novo Holdings and Qatar Investment Authority with participation from two undisclosed strategic investors. The company is developing a low-profile, high continuous flow percutaneous ventricular assist device for high risk PCI and cardiogenic shock.
On the move: Pharmacy care software company Omnicell announced that Perry A. Genova, PhD, will join the company as Senior Vice President, Chief Technology Officer, effective March 31. Dr. Genova, a 25-year industry veteran, previously served as Senior Vice President of Research and Development at EndoQuest Robotics.
The buzz: Pharmaceutical giant Eli Lilly has expanded its LillyDirect platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease, the majority of whom have not been formally diagnosed. The company will focus on education and pathways to connect people to independent provider options.
On the rise: AI-powered clinical intelligence company Navina raised $55 million in Series C funding, led by Growth Equity at Goldman Sachs Alternatives, with participation from existing investors, including Vertex Ventures Israel, Grove Ventures and ALIVE.
What’s next: According to a University of Florida study published in the Journal of the American Medical Association, AI-driven software is 96 percent accurate at diagnosing Parkinson's disease. The study was conducted across 21 sites, 19 of them in the United States and two in Canada.
